TAG:
WSI
Year’s Top 10 Lab Stories Contain Surprises & Twists
By Robert Michel | From the Volume XXX, Number 18 – December 26, 2023 Issue
CEO SUMMARY: With the SARS-CoV-2 pandemic now in the rearview mirror of the nation’s clinical labs and pathology groups, the important news stories of 2023 were mostly about developments where the consequences will influence laboratory operations in coming years. Artificial intelligence…
Artificial Intelligence: Now a Priority for Labs
By Robert Michel | From the Volume XXX, Number 17 – December 4, 2023 Issue
CEO SUMMARY: It’s time to recognize the field of artificial Intelligence as the next major source of disruption. Not only will clinical laboratories, anatomic pathology groups, and diagnostics companies be disrupted by AI-powered technologies, but experts predict that almost eve…
Digital Pathology Business Plan for Both Clinical and ROI Success
By Kristin Althea O’Connor | From the Volume XXX, No. 9 – June 19, 2023 Issue
CEO SUMMARY: More pathology groups are ready to consider adopting whole-slide imaging and digital pathology. The decision to proceed should only be made after identifying the clinica…
Artificial Intelligence ‘Invades’ Pathology, Billing
By R. Lewis Dark | From the Volume XXIX, No. 3 – February 22, 2022 Issue
Predictions about the potential of artificial intelligence (AI) to transform nearly every area of healthcare are about to become reality. For the profession of laboratory medicine, AI is making speedy inroads into two areas. The first is anato…
First Digital Path AI Tool Cleared for Market by FDA
By Robert Michel | From the Volume XXVIII, No. 13 – September 27, 2021 Issue
CEO SUMMARY: In a first for the anatomic pathology profession, the Food and Drug Administration (FDA) has cleared for market a digital pathology image analysis product intended to aid pathologists in the diagnosis of prostate cancer. Developed by New York City-based Paige, the Paige…
Digital Pathology Image Service Delivers AI via the Internet
By Robert Michel | From the Volume XXVIII, No. 13 – September 27, 2021 Issue
IN GERMANY, AN EMERGING DIGITAL PATHOLOGY (DP) COMPANY has introduced a novel feature that could be a low-cost way for pathology groups to access artificial intelligence (AI) for digital image analysis. This would appeal to pathologists who may be reluctant to invest the substantial cost and time req…
Pathology Groups Should Plan to Use Digital Pathology
WHEN AN ANATOMIC PATHOLOGY GROUP CONSIDERS IMPLEMENTING digital pathology and whole-slide imaging (WSI) for primary diagnosis, it must identify and understand a range of challenges and opportunities. “Every pathology group should start by considering how it will use the related technologies of a…
Expert Sees Pros, Cons In DP and WSI Systems
By Joseph Burns | From the Volume XXVI No. 13 – September 23, 2019 Issue
CEO SUMMARY: Now that the FDA has cleared two digital pathology systems for use in primary diagnosis, a growing number of pathology groups are taking up the question of whether and when they should adopt and use a digital pathology system and whole slide imaging. One pathologist with hand…
Outside US, Digital Path Moves Ahead Rapidly
By Joseph Burns | From the Volume XXVI No. 10 – July 22, 2019 Issue
CEO SUMMARY: Implementation of digital pathology and whole-slide imaging systems in the United States lags behind that of other countries for two reasons. One is a more acute shortage of pathologists in those countries and the other is a less restrictive regulatory environment. In some lo…
FDA Clears Aperio’s Digital Pathology System
By Joseph Burns | From the Volume XXVI No. 10 – July 22, 2019 Issue
CEO SUMMARY: In May, the FDA announced clearance for Leica Biosystems to market its Aperio AT2 DX System for clinical diagnosis in the United States. The Aperio AT2 DX System is intended for in vitro diagnostic use as an aid to pathologists reviewing and interpreting digital images of sur…
CURRENT ISSUE
Volume XXXI, No. 5 – April 8, 2024
The fragmentation of consumer markets is reflected in clinical lab services, and The Dark Report examines this trend and how it will impact labs in the coming years. Also, The Dark Report notes that the FDA has issued a controversial memo to reclassify many high-risk IVD assays.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized
The Dark Report • 21806 Briarcliff Dr • Spicewood, TX 78669
Phone: 512-264-7103 • Toll Free Number: 800-560-6363
Email: customerservice@darkintelligencegroup.com
© 2022 The Dark Report. All rights reserved.